Reprint

Current Insights on Lipid-Based Nanosystems

Edited by
January 2023
368 pages
  • ISBN978-3-0365-6166-0 (Hardback)
  • ISBN978-3-0365-6165-3 (PDF)

This is a Reprint of the Special Issue Current Insights on Lipid-Based Nanosystems that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Lipid-based nanosystems, including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), cationic lipid nanoparticles, nanoemulsions, and liposomes, have been extensively studied to improve drug delivery through different administration routes. The main advantages of these systems are their ability to protect, transport, and control the release of lipophilic and hydrophilic molecules (either small-molecular-weight molecules or macromolecules); the use of generally recognized as safe (GRAS) excipients that minimize the toxicity of the formulations; and the possibility to modulate pharmacokinetics and enable the site-specific delivery of encapsulated payloads. In addition, the versatility of lipid-based nanosystems has further been demonstrated for the delivery of vaccines, the protection of active cosmetic ingredients, and the improvement of moisturizing properties of cosmetic formulations.Lipid-based nanosystems are well established and there are already different commercially approved formulations for various human disorders. This success has paved the way for the diversification of the pipeline of development, to address unmet medical needs for several indications, such as cancer, neurological disorders, and autoimmune, genetic, and infectious diseases.This Special Issue aims to update readers on the latest research on lipid-based nanosystems, both at the preclinical and clinical levels. A series of 15 articles (six reviews and nine studies) is presented, with authors from 12 different countries, showing the globality of the investigations that are being carried out in this area.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
Echinococcus granulosus; scolicidal; nanoliposome; juglone; apoptotic activity; hydrogel; SLNs; nose-to-brain delivery; mucoadhesion; quality by design; antioxidant activity; nasal administration; nanostructured lipid carriers; solid lipid nanoparticles; in vitro cell cultures; 3D nasal casts; lung cancer; targeted drug delivery; lipid-based nanocarriers; pulmonary delivery; dry powder inhalers; aerosols; liposomes; nanoemulsions; nanotechnology; biologically active compounds; dermal drug delivery; liposomes; nanoemulsions; nanostructured lipid carriers; polyphenols; phytophenols; solid lipid nanoparticles; skin permeation; chemotherapy; radiotherapy; active targeting; passive targeting; tumor; immunoconjugate; traditional liposome; stealth liposome; triggered release; limitations of liposomes; drug transfer; in vitro release; colloidal drug carriers; lipid nanoparticles; hydrogel beads; cholesteryl nonanoate; bovine serum albumin; skin diseases; lipid-based nanosystems; solid lipid nanoparticles; nanostructured lipid carriers; cream; ointment; gel; pH-sensitive; liposome; imidazole; anticancer; drug delivery; multicellular spheroids; dapagliflozin; solid lipid nanoparticles; Box–Behnken design; FTIR; DSC; XRD; SEM; AFM; in vitro Franz diffusion cells; lipid-based nanoparticles; nanocarrier; surface charge; delivery systems; chronic treatment; mice; anti-oxidant activity; hepatoprotective effect; phospholipid; phytosomes; Silymarin; Colorectal Cancer; Niosomes; Oxaliplatin; Paclitaxel; d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS); lipid nanoparticles; drug delivery; therapeutic nucleic acids; schizophrenia; quetiapine fumarate; glycerosomes; central composite rotatable design; bioavailability; pharmacokinetic; n/a